MRNA

Moderna
D

MRNA

27.140
USD
-1.20
(-4.23%)
Market Closed
Volume
569,148
EPS
-10
Div Yield
-
P/E
-3
Market Cap
10,492,937,473
Signals
Abdilatif
Abdilatif
1 year ago
sell
MRNA
MRNA@101.02
2024-02-01 04:45
MRNA@101.02 Chart
Profit
357.00
Abdilatif
Abdilatif
1 year ago
sell
MRNA
MRNA@101.83
2024-01-29 05:09
MRNA@101.83 Chart
Profit
-175.00
More
Related Instruments
AZN
AZN
-0.910
(-1.24%)
72.590 USD
BNTX
BNTX
-0.840
(-0.92%)
90.220 USD
GSK
GSK
-0.890
(-2.30%)
37.880 USD
I
INO
-0.12500
(-7.69%)
1.50000 USD
JNJ
JNJ
-12.560
(-7.58%)
153.240 USD
MRK
MRK
-2.580
(-2.88%)
87.120 USD
N
NVAX
-0.40500
(-6.32%)
6.00000 USD
PFE
PFE
-0.785
(-3.10%)
24.550 USD
T
TDOC
-0.18500
(-2.33%)
7.76500 USD
More
News

Title: Moderna

Sector: Healthcare
Industry: Biotechnology
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Risk Disclosure: Trading in financial instruments involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks. Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed. Arincen would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Arincen and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website. It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Arincen and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website. Arincen may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.